News | October 24, 2011

American College of Cardiology Launches PINNACLE-AF Outpatient Registry


October 24, 2011 – The American College of Cardiology (ACC) announced it is expanding its outpatient PINNACLE Registry with a new platform focusing on atrial fibrillation (AF), including the next generation of anticoagulants.

 The new platform, PINNACLE-AF, will operate within the existing PINNACLE Registry.  The PINNACLE Registry is the largest cardiovascular outpatient database in the United States and is part of the ACC’s National Cardiovascular Data Registry (NCDR). NCDR is the most comprehensive, outcomes-based cardiovascular patient data registry for quality improvement in the United States.

“The expansion of the PINNACLE Registry is coming at a time when new treatments for atrial fibrillation are coming online,” said Jack Lewin, M.D., CEO of the American College of Cardiology. “In this context of innovation, PINNACLE can provide a means to monitor practice pattern changes over time while we rigorously assess current practice patterns and help providers evaluate and improve adherence to established guidelines and performance measures. The expansion will also provide a deeper data repository for future research and innovation.”

PINNACLE currently has 2.1 million patient records representing valid patient encounters from hundreds of outpatient practices nationwide. Of those patients, over 100,000 have atrial fibrillation. Participation in the registry is free to all cardiology practices.

Atrial fibrillation is a cardiac rhythm disorder in which the upper chambers of the heart, the atria, beat irregularly and out of sync with the two lower chambers. Symptoms include an irregular or rapid heart rate, shortness of breath, and weakness.  While AF itself is not commonly fatal, it often is associated with increased risks of death and stroke. 

For more information: www.PINNACLEregistry.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now